Why most randomized phase II cervical cancer chemoprevention trials are uninformative: lessons for the future

J Natl Cancer Inst. 2001 Sep 5;93(17):1293-6. doi: 10.1093/jnci/93.17.1293.
No abstract available

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anticarcinogenic Agents / administration & dosage
  • Anticarcinogenic Agents / therapeutic use*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor
  • Biopsy
  • Carcinoma, Squamous Cell / prevention & control
  • Clinical Trials, Phase II as Topic
  • Colposcopy
  • Drug Administration Schedule
  • Female
  • Humans
  • Neoplasm Staging
  • Outcome Assessment, Health Care*
  • Papillomaviridae / isolation & purification
  • Predictive Value of Tests
  • ROC Curve
  • Randomized Controlled Trials as Topic
  • Research Design
  • Sensitivity and Specificity
  • Uterine Cervical Dysplasia / prevention & control
  • Uterine Cervical Neoplasms / prevention & control*
  • Uterine Cervical Neoplasms / virology

Substances

  • Anticarcinogenic Agents
  • Antineoplastic Agents
  • Biomarkers, Tumor